〔Abstract〕 Objective To investigate the curative effect and safety of venolazine combined with bifidobacterium triple viable enteric capsule in the treatment of helicobacter pylori (Hp) infection. Methods A total of 120 Hp infected patients admitted to Zhangpu County Hospital from January 2023 to August 2023 were divided into two groups according to different treatment methods. The control group was given bismuth quadruple therapy, and the observation group was given venolazine fumarate, amoxicillin capsules and bifidobacterium triple viable enteric capsule.The clinical symptom remission rate, Hp eradication rate, inflammatory indicators and adverse reactions were compared between the two groups after treatment. Results The symptom remission rate (98.33%) of the observation group was higher than that of the control group (85.00%), the eradication rate of Hp (96.67%) was higher than that of the control group (85.00%), and the incidence of adverse reactions (1.67%) was lower than that of the control group (13.33%), with statistical significance (P < 0.05). The levels of serum interleukin-6 (IL-6) and hypersensitive C-reactive protein (hs-CRP) in the observation group were lower than those in the control group after 14 days of treatment, and the differences were statistically significant (P < 0.05). Conclusion The clinical symptom remission rate and eradication rate of Hp infection were higher in the treatment of Hp infection with venolazine combined with bifidobacterium triple viable enteric capsule, which could effectively reduce the inflammatory response of patients and reduce adverse drug reactions.